Clinical trials: Stage IIA Non-small Cell Lung Cancer
Solid Tumor
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6…
- Trial name
- NCT04503278
- Testing
- CLDN6 CAR-T, CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- Where
- 12 sites in Australia, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- BioNTech Cell & Gene Therapies GmbH
Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients
The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer.
- Trial name
- PULMO-01 (NCT06879717)
- Testing
- roginolisib, Dostarlimab, Docetaxel
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 45 people
- Sponsor
- iOnctura
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of DM005 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
- Trial name
- NCT06515990
- Testing
- DM005
- Where
- 6 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Doma Biopharmaceutical（Suzhou）Co., Ltd.
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease…
- Trial name
- NCT00034541
- Testing
- cetuximab, paclitaxel, carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1…
- Trial name
- NCT07444437
- Testing
- LM103 TILs Injection, PD-1 / PD-L1 monoclonal antibody
- Where
- 5 sites in China
- Volunteers
- 45 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Urinary Bladder Neoplasms, Colorectal Cancer
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT05397171
- Testing
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Where
- 6 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer
Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell lung cancer (SCLC) patients without disease progression after first-line platinum containing chemotherapy, objective response rate (ORR)…
- Trial name
- NCT04890795
- Testing
- AL8326 tablets
- Where
- 9 sites in China
- Volunteers
- 237 people
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Non-small Cell Lung Cancer
An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with Platinum-Gemcitabine based doublet first line therapy in stage IV non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT01844791
- Testing
- OCZ103-OS, Platinum, Gemcitabine
- Where
- Poland
- Volunteers
- 25 people
- Sponsor
- Oncozyme Pharma Inc.
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC)
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants…
- Conditions
- Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
- Trial name
- ALAFOSS-01 (NCT06599502)
- Testing
- AZD0022, Cetuximab
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
- Trial name
- NCT02179671
- Testing
- Gefitinib, AZD9291, Selumetinib+Docetaxel
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with relapsed stage IIIB or IV non small cell lung cancer.
- Trial name
- NCT00034164
- Testing
- S-8184 Paclitaxel Injectable Emulsion
- Where
- Russia
- Volunteers
- 52 people
- Sponsor
- Achieve Life Sciences
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed.
- Trial name
- UV1-hTERT2012L (NCT01789099)
- Testing
- UV1 synthetic peptide vaccine and GM-CSF
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Ultimovacs ASA
Stage IB-IIIA Non-small Cell Lung Carcinoma
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without…
- Trial name
- ADAURA (NCT02511106)
- Testing
- AZD9291 80 mg/40 mg, Open-label AZD9291 80 mg/40 mg
- Where
- 238 sites in United States, Australia and 23 more
- Volunteers
- 682 people
- Sponsor
- AstraZeneca
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Non Small Cell Lung Cancer
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
This is a phase I/IIa open, uncontrolled, international, prospective clinical trial, in an out-patient setting, in patients with stage IIIB/IV NSCLC.
- Trial name
- NCT00923312
- Testing
- CV9201
- Where
- 14 sites in Germany, Switzerland
- Volunteers
- 46 people
- Sponsor
- CureVac
Advanced Solid Tumor
Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
This study is a Phase I/IIa, multi-center, open-label study of BR790 in combination with Tislelizumab with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.
- Trial name
- NCT05505877
- Testing
- BR790+Tislelizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Gopherwood Biotech Co., Ltd.
Squamous Non-Small Cell Lung Cancer
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
The main purpose of the study was to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with treatment-naïve advanced squamous non-small-cell lung…
- Trial name
- NCT03717155
- Testing
- Avelumab, Cetuximab, Gemcitabine
- Where
- 20 sites in Hungary, Serbia and 1 more
- Volunteers
- 43 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Non Small Cell Lung Cancer
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with advanced…
- Trial name
- NCT04032847
- Testing
- ATL001, Pembrolizumab
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 27 people
- Sponsor
- Achilles Therapeutics UK Limited